A股異動 | 全球搶購 裝載疫苗的玻璃瓶已出現緊缺跡象 相關概念股走強
格隆匯12月1日丨在新冠疫苗即將量產之際,裝載疫苗的玻璃瓶已出現緊缺跡象。全球範圍內,幾乎所有參與新冠疫苗研製的生物醫藥公司都在排隊搶購疫苗瓶。公開資料顯示,僅強生一家公司就已購買了2.5億個疫苗瓶。機構預測,若每人接種3次,新冠疫苗全球滲透率達到20%時,需要疫苗瓶50億支,全球滲透率達到70%時,需要疫苗瓶將近160億支。疫苗是化學制劑,一旦與玻璃瓶發生化學反應,就會被污染,產生安全隱患。因此疫苗所用的玻璃瓶並非普通的玻璃瓶,而是中硼硅玻璃瓶。相關概念股走強,正川股份漲近6%,山東藥玻漲3.43%。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.